Investigational drug · Phase 2
Ravagalimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rheumatoid Arthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "Ravagalimab"
First trial start
2025
Jun 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ravagalimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Ravagalimab" as an intervention, largest first.
- A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06972446 · 180 participants (planned) · Start Jun 20, 2025 · Primary completion Feb 2027
Drug: Lutikizumab; Placebo and 1 more · For: Rheumatoid Arthritis
Sites: Peoria, Arizona; Jonesboro, Arkansas; Beverly Hills, California · 96 sites in all
AbbVieAbbVie (ABBV)
NCT03695185 · 42 participants · Start Mar 26, 2019 · Primary completion Apr 5, 2021
Drug: Ravagalimab 600 mg; Ravagalimab 300 mg · For: Ulcerative Colitis (UC)
Sites: Tucson, Arizona; Huntington Beach, California; Lakewood, California · 34 sites in all
AbbVieAbbVie (ABBV)
NCT06402513 · 12 participants · Start Jun 24, 2024 · Primary completion Oct 8, 2024
Drug: Ravagalimab · For: Healthy Volunteers
Sites: Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT05217472 · 0 participants · Start Mar 6, 2020 · Primary completion Apr 15, 2022
Drug: Ravaglimab; Ravagalimab and 2 more · For: Sjogren's Syndrome (SS)
Sites: Utrecht, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial.
Peyrin-Biroulet L, Seenan JP, Armuzzi A, et al. · Adv Ther 2026
- CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
Argiriadi MA, Benatuil L, Dubrovska I, et al. · BMC Mol Cell Biol 2019
Also in development for Rheumatoid Arthritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.